Considering that the JAK–STAT signaling cascade plays a major role in CTCL pathogenesis and may therefore be a promising target for CTCL treatment, the evaluation of different biomarkers and genes and their targeting would be useful for improving CTCL treatment options [22,36,37]. Here, SOAT1 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.